Entyvio produces higher UC remission rates than anti-TNF

Patients with ulcerative colitis who received Entyvio in routine practice experienced higher rates of remission than those treated with anti-TNF agents, according to study results.Parambir Dulai, MD, of the division of gastroenterology at the University of California, San Diego, and colleagues wrote that recent phase 3 studies demonstrated the superiority of Entyvio (vedolizumab, Takeda) over anti-TNF, but more information is needed on how effective it is in everyday practice.“Although informative in helping to understand the relative positioning of these biologics, nearly 75% of UCRead More

Share on facebook
Share on twitter
Share on linkedin